Objectives of the Project
Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown cause, which leads to disability and may cause premature death. SSc is characterized by massive accumulation of extracellular matrix proteins (=fibrosis) in skin and internal organs with permanent loss of
Decreasing/reversing fibrosis in patients with SSc can improve the prognosis of thisdevastating disease. Drugs that influence metabolic pathways could reduce the production of extracellular matrix proteins by fibroblasts in SSc. This represents a promising new treatment strategy in SSc.